Dergiler / Journal of Health Sciences and Medicine / 2022 / Cilt: 5 - Sayı: 1

Effect of SARS-CoV-2 pandemic on breast cancer stage at diagnosis

Sayfa
62–66
Yayın Tarihi
2022-01-17
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

We predict that statistically significant results will be obtained in studies with a larger number of cases.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: We aimed to research the effects of the COVID-19 pandemic on breast cancer stages at the time of diagnosis.
📊
Temel Bulgular & Veri:Material and Method: The data of female patients over 18 who underwent breast surgery and sentinel lymph node sampling for malignancy between 01.06.2019 and 31.11.2019 with between 01.06.2020 and 31.11.2020 were analyzed.
💡
Sonuç & Katkı:We predict that statistically significant results will be obtained in studies with a larger number of cases.
🔬Tür:Araştırma Makalesi
📍Kapsam:2019 Verileri
⚙️Değişkenler:covid-19 · breast cancer · sentinel lymp node

Abstract

Objective: We aimed to research the effects of the COVID-19 pandemic on breast cancer stages at the time of diagnosis. Material and Method: The data of female patients over 18 who underwent breast surgery and sentinel lymph node sampling for malignancy between 01.06.2019 and 31.11.2019 with between 01.06.2020 and 31.11.2020 were analyzed. Patients were divided into two groups as before and during the pandemic. Results: Data of 55 patients in total were reached, of which 31 were diagnosed before the pandemic and 24 after the pandemic. There is no significant difference between the two groups in terms of age. Average tumor size is 3.42±2.00 cm, and 18 patient (32.7%) has positive sentinel lymph node biopsy (SLNB). In before pandemic group (Group 1) SLNB positivity rate is only 25.8% (n=8) but in during pandemic group (Group 2) this rate reaches 41.7% (n=10), but this is not statistically significant(p=0.214). While the tumor size of the patients in Group 1 was 3.35±2.25 cm, it was 3.51±1.67 cm in Group 2. Still, no statistically significant difference was observed (p=0.141). Conclusion: As a result of our study, although statistically insignificant, an increase in tumor sizes and positive lymph node numbers was detected. We predict that statistically significant results will be obtained in studies with a larger number of cases.

🔖

Bu Makaleye Atıf Yap

ÖZKAN, M. B., YILDIRIM, M. B., TOPCU, R., TURHAN, V. B. (2022). Effect of SARS-CoV-2 pandemic on breast cancer stage at diagnosis. Journal of Health Sciences and Medicine, Cilt: 5 - Sayı: 1, 62–66. https://ajindex.com/articles/776646

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama 2020; 323: 1239-42. Organization WH. Novel Coronavirus (2019-nCoV). Situation Report–22, Data as reported by 11 February 2020. 2020.
  2. Buonomo OC, Materazzo M, Pellicciaro M, Caspi J, Piccione E, Vanni G. Tor Vergata University-Hospital in the beginning of COVID-19-Era: Experience and recommendation for breast cancer patients. in vivo 2020; 34: 1661-5.
  3. Lai AG, Pasea L, Banerjee A, et al. Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency. MedRxiv 2020.
  4. Maringe C, Spicer J, Morris M, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol 2020; 21: 1023-34.
  5. İnanç İH, Bursa N, Gültepe A, Şabanoğlu C. The impact of COVID-19 on rural population: A retrospective study. J Health Sci Med 2021; 4: 722-7.
  6. Ekiz İşcanlı İG, Şaylan B. Evaluation of factors which determining survival of SARS COV-2 infected patients in intensive care unit. Anatolian Curr Med J 2021; 3: 36-43.
  7. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 2021;71: 209-49.
  8. Marmot MG, Altman D, Cameron D, Dewar J, Thompson S, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer 2013; 108: 2205-40.
  9. Figueroa JD, Gray E, Pashayan N, et al. The impact of the COVID-19 pandemic on breast cancer early detection and screening. Prevent Med 2021; 151: 106585. Peng SM, Yang KC, Chan WP, et al. Impact of the COVID‐19 pandemic on a population‐based breast cancer screening program. Cancer 2020; 126: 5202-5.
  10. Shimazu K, Tamaki Y, Taguchi T, Takamura Y, Noguchi S. Comparison between periareolar and peritumoral injection of radiotracer for sentinel lymph node biopsy in patients with breast cancer. Surgery 2002; 131: 277-86.
  11. Pijpers R, Meijer S, Hoekstra OS, et al. Impact of lymphoscintigraphy on sentinel node identification with technetium-99m-colloidal albumin in breast cancer. J Nuclear Med 1997; 38: 366-8.
  12. Curigliano G, Cardoso MJ, Poortmans P, et al. Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic. The Br